OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Targeting the STING pathway is a promising ImmunoOncology strategy as it stimulates the innate immune system and enhances tumor immunogenicity. With significant heterogeneity in allelic variants of the STING gene within the human population, PP316 STING Human Variant Panel enables a quick assessment of STING functional activity against various human STING variants. This panel covers the diverse human STING heterogeneity, offering valuable insights for the design of novel STING agonists in anti-cancer drug discovery.
No. of Assays on Panel:
7
Assays on Panel:
Family
Immune System
Name
STING WT Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355910-0
Protein
STING_HUMAN
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING G230A Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355912-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING AQ Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355913-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING HAQ Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355914-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING R232H Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355915-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING R293Q Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355916-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family
Immune System
Name
STING R71H Variant Human PRR Cell Based Agonist Reporter LeadHunter Assay - TW
Item
355917-0
Protein
Organism
Human
Assay Sub Type
Cell Based
Family:
Oncology
Class:
PRR
Organism:
Human
Construct Details:
Full Length, Recombinant
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Agonist
Platform:
Plate reader
Testing Information
Criteria For Significance:
≥ 50% response of 2'3'-cGAMP-induced luminescence
Test Concentration / Dose:
Suggested concentration for initial testing is 10 µM
Test Sample Requirements:
Minimum: 300 μl of 10 mM stock -OR- 2 mg pre-weighed powder (assuming FW ≤ 500 and purity 100%).
Turnaround Time
Standard:
20 Business Days
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Adverse / Beneficial Action:
Potential benefit in treatment of cancer and modulation of immune responses
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
